Teva Pharmaceutical (TEVA)

Re: Teva Pharmaceutical (TEVA)

Postby winston » Tue Nov 07, 2017 7:20 am

not vested

Teva Survives Price Cut As Billionaire Reportedly Mulls Stake

by ALLISON GATLIN

Credit Suisse analyst Vamil Divan trimmed his price target on Teva to 8 from 14, and kept his underperform rating.

Mylan (MYL) just launched a generic version of Copaxone, a multiple sclerosis drug from Teva. Now, Divan sees Teva pulling in $1.01 billion in U.S. Copaxone sales next year, down 71% year over year.


Source: IBD

https://www.investors.com/news/technolo ... yptr=yahoo
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118541
Joined: Wed May 07, 2008 9:28 am

Re: Teva Pharmaceutical (TEVA)

Postby winston » Fri Nov 24, 2017 10:41 pm

not vested

Struggling Teva Announces Mass Layoffs

Summary

Teva announced it layoff of up to 25% of its workforce in Israel.
Generic Copaxone could render Teva insolvent regardless of cost cuts.
All signs point to a dilutive equity raise.
Sell TEVA.

Copaxone represents over 45% of the company's EBITDA and Teva needs to rapidly grow revenue or cut costs to compensate for the loss.


The plan could see up to 25 percent slashed from the 6,860-member local workforce, and an overall cutback of 20% from its total global employee numbers of around 57,000.


Source: Seeking Alpha

https://seekingalpha.com/article/412741 ... ngcom_feed
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118541
Joined: Wed May 07, 2008 9:28 am

Re: Teva Pharmaceutical (TEVA)

Postby winston » Fri Nov 24, 2017 10:45 pm

not vested

Despite all these setbacks, Pinxter Analytics believes that Teva's current valuation is not justified.

The author's investment thesis is based on three main points.

The first is that Teva's sales are still growing at around 2% on an organic basis. In addition, this does not take into account the fact Teva has 600 generics in the pipeline that could be potentially approved in the next two years, according to the author.

Further, the other notes that these generic launches, combined with a price reduction for Copaxone to compete with Mylan generic, could lead to organic sales growth returning to 4-5%.
The author believes that this will also lead to a higher earnings growth rate.

Finally, Pinxter Analytics adds that with the company continuing to generate high cash flows, making acquisitions in the future and reducing its debt are all factors that could enhance shareholder value.

Source: Seeking Alpha

https://seekingalpha.com/article/412710 ... ngcom_feed
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118541
Joined: Wed May 07, 2008 9:28 am

Re: Teva Pharmaceutical (TEVA)

Postby winston » Mon Nov 27, 2017 10:37 pm

not vested

Can Teva Pharmaceutical (NYSE:TEVA) make any more dumb mistakes than they already have?

At first, the declines in this mega-cap generic and ethical pharmaceutical company were the result of a whole series of self-induced wounds by self-aggrandizing executives looking to secure their legacy, but now?

Now it has less to do with fundamentals and more to do with the three factors stated above; having lost two-thirds of its value, now it’s just investors piling on.

Could it get worse before it gets better? Any stock could. But there are patents here, and market share, that are enticing enough to make it worth your due diligence.

Source: Investing.com
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118541
Joined: Wed May 07, 2008 9:28 am

Re: Teva Pharmaceutical (TEVA)

Postby winston » Thu Dec 07, 2017 4:14 pm

2018 Tech Dog No 4: Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) CEO Kare Schultz, who took over the company in September, announced a restructuring plan two weeks ago that also included a management shakeup. But investors were disappointed.

See, Teva divides itself between generic and prescription drugs. To unlock value at the Israel-based firm, many investors had been hoping to see those operations split from each other.

Instead, Schultz said he is integrating them more deeply in a bid to improve efficiencies. There’s no reason to believe that Schultz’s plan will work out.

I certainly don’t.

Teva has racked up a lot of debt in recent years, has lost patent protections on a key branded drug, and has cut its earnings outlook twice in 2017.

And last August, it wrote down $6.1 billion in its generics unit, leading to a roughly $6 billion quarterly loss.

Let’s not forget that Teva’s investors have been down this road before. Jeremy Levin, who served as the company’s CEO briefly in the early 2010s, announced a turnaround in 2013 that included layoffs of about 5,000 workers.

But Levin then found himself forced out of a job. See, Israel provides Teva with billions in tax incentives, and lawmakers there hate to see workers get pink slips.

So, as we prepare to close the books on a record-breaking year for ground-floor trend investments like technology and Bitcoin, this is a time to really focus on stocks that can greatly improve your net worth…

… And avoid the dogs that can destroy it.

Source: Daily Alert
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118541
Joined: Wed May 07, 2008 9:28 am

Re: Teva Pharmaceutical (TEVA)

Postby winston » Mon Dec 11, 2017 10:22 pm

Teva: Is This What A Bloodbath Looks Like?

Summary:-

Market suggests Teva will lay off up to 10,000 employees. Is this what a bloodbath look like?

Teva's liquidity and cash flow could allow it to forgo an equity raise.

The arrival of generic Copaxone could trigger future ratings downgrades.

Generic competition and rising legal risks could prompt AGN to dump a sizeable chunk of TEVA shares to shore up its balance sheet.

TEVA remains a sell.

The company aims to reduce expenses by $1.5 billion to $2 billion over the next two years, with a little less than half of the cuts linked to research and development spending, the people said, asking not to be identified as the discussions are confidential.


10,000 people = 15% of Teva's employee base.


Source: Seeking Alpha

https://seekingalpha.com/article/413097 ... ngcom_feed
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118541
Joined: Wed May 07, 2008 9:28 am

Re: Teva Pharmaceutical (TEVA)

Postby winston » Mon Dec 11, 2017 10:27 pm

not vested

Teva Pharmaceutical: A Holiday Season Sale

by Bhavneesh Sharma, MBA

Summary

We bought Teva Pharmaceutical stock recently close to $10-$11/share earlier this month.
Shares are beaten down and could double in 2-3 years.
Our initiation rating is Buy, price target = $25 (2-3 years time frame).

The blockbuster drug for multiple sclerosis Copaxone represents about 45% of Teva's EBITDA and bears are betting that the approval of its generic version by Mylan (MYL) would result in the loss of this revenue stream.

Copaxone had $1B sales in Q3 2017 and accounts for 25% of the company's $20B in annual sales.


Other brand names of Teva like Azilect and ProAir are also facing patent cliffs.

Teva has $35B of debt on its balance sheet after a $40B acquisition of Allergan's (NYSE:AGN) generics business.


Source: Seeking Alpha

https://seekingalpha.com/article/412963 ... ngcom_feed
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118541
Joined: Wed May 07, 2008 9:28 am

Re: Teva Pharmaceutical (TEVA)

Postby winston » Wed Dec 13, 2017 7:57 pm

not vested

Teva Pharm to unveil restructuring plan on Thursday: report

The plan includes closing its research and development center in the coastal city of Netanya, selling its logistics center in Shoham and laying off a third of its 6,800 workers in Israel.

Considering cutting up to 10,000 jobs to reduce costs by $1.5 billion to $2 billion in the next two years.


Source: Reuters

https://www.reuters.com/article/us-teva ... h%20Report
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118541
Joined: Wed May 07, 2008 9:28 am

Re: Teva Pharmaceutical (TEVA)

Postby winston » Thu Dec 14, 2017 9:25 pm

Teva Pharm to lay off a quarter of workforce, suspends dividend

by Tova Cohen and Ari Rabinovitch

These measures will result in the reduction of 14,000 positions globally, with the majority of the cuts expected in 2018.

The two-year restructuring plan is intended to reduce Teva’s cost base by $3 billion by the end of 2019, out of an estimated cost base for 2017 of $16.1 billion.

Saddled with nearly $35 billion in debt.

Teva expects a restructuring charge from the plan in 2018 of at least $700 million.




Source: Reuters

https://www.reuters.com/article/us-teva ... ser%20List
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118541
Joined: Wed May 07, 2008 9:28 am

Re: Teva Pharmaceutical (TEVA)

Postby winston » Fri Dec 15, 2017 7:49 am

Teva’s new plan is to raise drug prices, but it won’t be easy

By Emma Court

External factors have been pressuring generic prices, so the company may not have much price-setting agency

“Some of them we will succeed, some we will not. And those where we will not — we will discontinue”.


“You’re looking at the tail end where I’m sure that probably the last 20% of your products might make up 80% of your losing products, and that’s why you’re going to be looking”.


Source: Market Watch

https://www.marketwatch.com/story/tevas ... yptr=yahoo
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118541
Joined: Wed May 07, 2008 9:28 am

PreviousNext

Return to S to Z

Who is online

Users browsing this forum: No registered users and 11 guests